In a letter to states and Union Territories, Union Health Secretary Rajesh Bhushan on Thursday said it has been observed that the uptake of precaution dose of Sputnik V is only 0.5 per cent of those due for it.
Panacea Biotec has the manufacturing rights of Sputnik V COVID-19 vaccine in India. Its share prices hit a high of Rs 198.50 on BSE.
Russian banks being barred from SWIFT adds to worries
The Russian COVID-19 vaccine Sputnik V has failed to take off in India despite being one of the first few vaccines approved and arrive but Sputnik Light, which is a single-dose vaccine, is expected to fare better, especially as it may be used as a booster shot.
The joint Russian-Italian study — funded by the Russian Direct Investment Fund which markets Sputnik V — compared the blood serum samples of people taken three to six months after the second dose of the two vaccines.
Australia says the Gamaleya Institute's two-dose jab is an “additional COVID-19 vaccine that would be recognised” but no such clearance has been given to single-dose Sputnik Light
When used as a booster shot, Russia's single-dose Sputnik Light helps develop a stronger antibody response against the Omicron variant, the study by the Gamaleya Institute developer was cited as saying.
The clarification comes after Russia’s Health Minister Mikhail Murashko in recent days reportedly said that administrative issues were among the main holdups in WHO’s decision-making process about whether to grant an emergency use listing to Sputnik V as it has for a half-dozen other vaccines.
The Sputnik V shot, widely used in Russia and approved for use in over 70 countries, is undergoing a review by the WHO and the European Medicines Agency (EMA). Their approval could open up new markets for the shot, especially in Europe.
According to RDIF, the single-dose Sputnik Light vaccine demonstrated 79.4 percent efficacy
The Union Health Ministry shared a list of parameters with the states and Union territories to identify the authentic versions of Covishield, Covaxin and Sputnik V vaccines.
As per the agreement, Panacea Biotec shall produce Sputnik V vaccine using the ready to fill drug substance manufactured by Generium in Russia, and then supply the entire quantity thereof to Dr Reddy's for distribution in India.
Dr Reddy's margins are likely to be weighed by recurring investments - digitization, brand building exercise & elevated R&D - in near to medium term
While the government aims to fully vaccinate 94 crore adults in the country by the end of December, it is possible that many do not turn up for the jabs given vaccine hesitancy.
On the 188th day of the vaccination drive on July 22, a total of 54,76,423 lakh jabs were administered across the country.
Gland Pharma trades at 30x EV/Ebitda for FY23, which is largely in line with some of its peers such as Syngene and Divi's Lab. Though we believe success in complex injectables holds further re-rating potential, here’s why we remain constructive on this steady earnings compounder and believe investors can accumulate during market-wide gyrations.
While the US market is still expected to clock 18-20 per cent growth for Gland Pharma in FY22, the company’s foray into non-US markets would accelerate growth in the medium term
On the 187th day of the vaccination drive on July 21, 22,77,679 lakh jabs were administered across the country.
So far, 39,13,40,491 doses of COVID-19 vaccines have been administered in India, the health ministry said.
The researchers noted that evidence from other vaccines offers support for the one-shot approach.
Serum Institute and RDIF plan to produce over 300 million doses of the Sputnik V vaccine in India per year.
"Starting initially in Hyderabad today, the soft launch rollout of Sputnik V has scaled up speedily and reached cities and towns all over India- including but not limited to Hyderabad, Vizag, Bengaluru, Mumbai, Navi Mumbai, Kolkata, Delhi, NCR, Chennai, Miryalaguda, Vijayawada, Baddi, Kolhapur, Kochi, Raipur, Chandigarh, Pune, Nagpur, Nashik it said in the tweet.
Dr. Reddy's had received about 3 million first doses by June 1 and about 360,000 doses of the second by early this month, the company and the Indian government have said.
Managing Director of Zydus Group Sharvil Patel says the company has invested Rs. 400-500 crore for the development of ZyCoV-D, the world’s first plasmid DNA vaccine for human use.